Cheraghlou Shayan, Agogo George O, Girardi Michael
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
J Am Acad Dermatol. 2023 Jul;89(1):70-80. doi: 10.1016/j.jaad.2019.08.058. Epub 2019 Aug 29.
Previous work has suggested that facility-level characteristics, such as case volume and academic affiliation, are associated with patient survival for rare malignancies. Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer with high mortality and rising incidence. The effect of facility characteristics on MCC outcomes is not yet established.
We aimed to investigate whether facility academic affiliation or case volume was associated with MCC patient survival.
We conducted a retrospective cohort analysis of US adult MCC cases diagnosed during 2004-2014 in the National Cancer Database.
Both facility academic affiliation (P < .001) and case volume (P < .001) were significantly associated with patient survival. The 5-year survival of patients treated at academic facilities was 63.0% (standard error [SE] 1.7) and that of a propensity score- matched cohort of patients treated at nonacademic facilities was 53.4% (SE 1.9). The 5-year survival of patients treated at high-case volume facilities was 67.4% (SE 2.1) and that of a propensity score-matched cohort of patients treated at low- and intermediate-case volume facilities was 58.6% (SE 2.0).
Disease-specific survival and local recurrence data were not available.
Treatment of MCC at academic and high-volume centers is associated with significantly improved patient survival. Further studies evaluating comorbidities and disease-specific survival are needed to establish whether experienced centers have improved outcomes in MCC treatment.
先前的研究表明,机构层面的特征,如病例数量和学术隶属关系,与罕见恶性肿瘤患者的生存率相关。默克尔细胞癌(MCC)是一种罕见的神经内分泌皮肤癌,死亡率高且发病率呈上升趋势。机构特征对MCC治疗结果的影响尚未明确。
我们旨在调查机构的学术隶属关系或病例数量是否与MCC患者的生存率相关。
我们对2004 - 2014年期间在美国国家癌症数据库中诊断出的成年MCC病例进行了回顾性队列分析。
机构的学术隶属关系(P <.001)和病例数量(P <.001)均与患者生存率显著相关。在学术机构接受治疗的患者5年生存率为63.0%(标准误[SE] 1.7),在非学术机构接受倾向评分匹配队列治疗的患者5年生存率为53.4%(SE 1.9)。在高病例数量机构接受治疗的患者5年生存率为67.4%(SE 2.1),在低和中等病例数量机构接受倾向评分匹配队列治疗的患者5年生存率为58.6%(SE 2.0)。
无法获取疾病特异性生存率和局部复发数据。
在学术机构和高病例数量中心治疗MCC与患者生存率显著提高相关。需要进一步研究评估合并症和疾病特异性生存率,以确定经验丰富的中心在MCC治疗中是否改善了治疗结果。